{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:08:04Z","timestamp":1770340084097,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T00:00:00Z","timestamp":1293753600000},"content-version":"vor","delay-in-days":244,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Objective.<\/jats:italic> Medical abortion using mifepristone followed by misoprostol is increasingly used for termination of an unwanted pregnancy. Consequently, an increasing number of women undergo medical abortion while still breastfeeding from a previous pregnancy. But there are no data on mifepristone use during lactation. We studied the levels of mifepristone in breast milk collected from women undergoing medical abortion. <jats:italic>Design and samples.<\/jats:italic> Samples of milk were collected from 12 women during the first 7 days after intake of either 200 mg (<jats:italic>n<\/jats:italic> = 2) or 600 mg (<jats:italic>n<\/jats:italic> = 10) of mifepristone. In addition, serum samples were collected on day 3 (<jats:italic>n<\/jats:italic> = 4). <jats:italic>Main outcome measures.<\/jats:italic> The levels of mifepristone, quantified using radioimmunoassay. <jats:italic>Results.<\/jats:italic> The milk concentrations of mifepristone were highest in the first samples collected during the first 12 hours following drug intake, and ranged from undetectable (&lt; 0.013 \u03bcmol\/l) to 0.913 \u03bcmol\/l. Thereafter, declining concentrations of mifepristone were detected up to 7 days. The lowest levels of mifepristone in milk were measured following ingestion of the 200 mg dose. The milk:serum ratio of mifepristone ranged from &lt; 0.013:1 to 0.042:1 on day 3 (<jats:italic>n<\/jats:italic> = 4). The calculated relative infant dose (RID) was 1.5% at its highest. <jats:italic>Conclusions.<\/jats:italic> The levels of mifepristone in milk are low, especially when using the 200 mg dose. Breastfeeding can be safely continued in an uninterrupted manner during medical abortion of this kind.<\/jats:p>","DOI":"10.3109\/00016341003721037","type":"journal-article","created":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T06:31:55Z","timestamp":1270103515000},"page":"618-622","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Medical abortion in lactating women \u2013 low levels of mifepristone in breast milk"],"prefix":"10.1111","volume":"89","author":[{"given":"INGRID","family":"S\u00c4\u00c4V","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHRISTIAN","family":"FIALA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JONNA M","family":"H\u00c4M\u00c4L\u00c4INEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"OSKARI","family":"HEIKINHEIMO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KRISTINA","family":"GEMZELL\u2010DANIELSSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,12,31]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"Available online at:http:\/\/www.stakes.fi\/FI\/tilastot\/aiheittain\/Lisaantyminen\/raskaudenkeskeytykset\/raskaudenkeskeytykset_ennakko.htm. (accessed on June 28 2009)"},{"key":"e_1_2_6_3_2","unstructured":"Available online at:http:\/\/www.socialstyrelsen.se\/NR\/rdonlyres\/93831CA6\u201090A3\u20104755\u20108BCE\u2010CD6EABCD6209\/13853\/200912510_rev3.pdf. (accessed on June 28 2009)"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.307.6906.714"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2307\/2136257"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.03.018"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.siny.2004.09.016"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2.6.947"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(77)90062-2"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/0002-9378(77)90741-4","article-title":"d\u2010Norgestrel concentrations in maternal plasma, milk and child plasma during administration of oral contraceptives to nursing women","volume":"15","author":"Nilsson S","year":"1977","journal-title":"Am J Obstet Gynecol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(03)00133-1"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(87)90160-9"},{"key":"e_1_2_6_13_2","first-page":"298","article-title":"Pharmacokinetics of the antiprogesterone RU486: no correlation to clinical performance of RU486","volume":"123","author":"Heikinheimo O","year":"1990","journal-title":"Acta Endocrinol"},{"key":"e_1_2_6_14_2","unstructured":"Available online at:http:\/\/emc.medicines.org.uk\/document.aspx?documentId=617#furtherInfo. (accessed on June 28 2009)"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(86)80017-8"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/oxfordjournals.humrep.a137358","article-title":"Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of pregnancy","volume":"6","author":"Hill NC","year":"1991","journal-title":"Hum Reprod"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(98)00284-1"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200010000-00012"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1945.tb16864.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(02)00355-X"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.05.008"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dem098"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2007.09.004"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb04078.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00111-7"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3109%2F00016341003721037","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.3109\/00016341003721037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T01:35:01Z","timestamp":1698716101000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.3109\/00016341003721037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.3109\/00016341003721037"],"URL":"https:\/\/doi.org\/10.3109\/00016341003721037","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"2010-12-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}